Senseonics Holdings, Inc.
NASDAQ:SENSMedical - Devices
-$0.09 today
- Market cap
- $533.56M
- Beta
- 0.97
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.90
Volume 0.87M
Average 0.71M
SENS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Senseonics Holdings, Inc.NASDAQ: SENS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $8.61M rose 18.0% year over year, ahead of the -13.4% change in trailing-twelve-month research & development. Sequentially, it fell 2.4% from the prior quarter. Over 3 fiscal years it compounded at -7.3% a year.
Context
- Research & development amounted to 89.6% of revenue in FY2025, down 93.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.0% holds above the trailing-twelve-month pace of -13.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 31.59M USD
- Year-over-year change
- -23.2%
- 4-year CAGR
- +3.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.59M | -23.2% |
| FY2024 | 2024-12-31 | 41.14M | -15.6% |
| FY2023 | 2023-12-31 | 48.75M | +22.7% |
| FY2022 | 2022-12-31 | 39.72M | +45.9% |
| FY2021 | 2021-12-31 | 27.22M | — |
Research & Development vs competitors
How SENS compares with its peers on the latest reported figures
- SENS's LTM Mar 2026 research & development of $32.9M is the lowest of the 6 companies compared; the peer median is $345.9M.
- Its year-over-year change of -13.4% is the 4th highest of 5, against a peer median of +19.5%.
- Research & development amounts to 80.8% of revenue for SENS, versus a peer median of 13.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $604M | +6.3% | +7.4% | 12.2% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $439M | — | +1.5% | 13.6% |
| LTM Jun 2026 | $345.9M | +39.2% | +18.7% | 11.3% | |
| LTM Mar 2026 | $188.1M | -32.4% | +0.9% | 18.3% | |
| LTM Mar 2026 | $37.56M | +32.7% | +3.4% | 34.1% | |
| LTM Mar 2026 | $32.9M | -13.4% | -7.3% | 80.8% | |
| Peer median (excluding SENS) | $345.9M | +19.5% | +3.4% | 13.6% | |
Competitors are the stored peer set for SENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.68M | 16.39M | 22.39M | 22.47M | 35.26M |
| Cost of Revenue | 14.49M | 13.66M | 19.3M | 21.94M | 19.49M |
| Gross Profit | (811K) | 2.73M | 3.09M | 533K | 15.76M |
| Gross Margin | -5.9% | 16.6% | 13.8% | 2.4% | 44.7% |
| Research & Development | 27.22M | 39.72M | 48.75M | 41.14M | 31.59M |
| Selling, General & Admin | 29.15M | 31.63M | 29.94M | 34.23M | 52.51M |
| Operating Expenses | 56.37M | 71.35M | 78.69M | 75.38M | 84.1M |
| Depreciation & Amortization | 1.24M | 985K | 1.28M | 1.48M | 1.51M |
| EBITDA | (284.52M) | 161.81M | (48.01M) | (68.7M) | (62.65M) |
| EBITDA Margin | -2080.5% | 987.3% | -214.4% | -305.7% | -177.7% |
| Operating Income | (57.18M) | (68.63M) | (75.6M) | (74.84M) | (68.34M) |
| Operating Margin | -418.1% | -418.7% | -337.7% | -333.0% | -193.8% |
| Interest Income | 243K | 1.82M | 5.36M | 4.5M | 4.2M |
| Interest Expense | 16.72M | 18.7M | 11.11M | 8.44M | 4.95M |
| Other Income / Expenses | (245.29M) | 210.75M | 15.21M | (3.77M) | (776K) |
| Income Before Tax | (302.47M) | 142.12M | (60.39M) | (78.62M) | (69.11M) |
| Pre-Tax Margin | -2211.9% | 867.2% | -269.7% | -349.8% | -196.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (302.47M) | 142.12M | (60.39M) | (78.62M) | (69.11M) |
| Net Margin | -2211.9% | 867.2% | -269.7% | -349.8% | -196.0% |
| EPS (Basic) | (14.40) | 6.07 | (2.20) | (2.50) | (1.66) |
| EPS (Diluted) | (14.40) | (2.17) | (2.20) | (2.50) | (1.66) |
| Weighted Avg Shares | 21.12M | 23.4M | 28.4M | 31.49M | 41.73M |
| Weighted Avg Shares (Diluted) | 21.12M | 30.91M | 28.4M | 31.49M | 41.73M |
Senseonics Holdings, Inc.
NASDAQ:SENS
Intrinsic Alpha fair value
Locked
Current Price
$9.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.